Checkpoint Capital L.P. Phathom Pharmaceuticals, Inc. Transaction History
Checkpoint Capital L.P.
- $202 Billion
- Q3 2024
A detailed history of Checkpoint Capital L.P. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Checkpoint Capital L.P. holds 1,504,307 shares of PHAT stock, worth $12.2 Million. This represents 13.49% of its overall portfolio holdings.
Number of Shares
1,504,307
Previous 875,000
71.92%
Holding current value
$12.2 Million
Previous $9.01 Billion
201.78%
% of portfolio
13.49%
Previous 5.43%
Shares
4 transactions
Others Institutions Holding PHAT
# of Institutions
144Shares Held
73.6MCall Options Held
42.3KPut Options Held
45.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$82.3 Million9.84% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$60.8 Million28.04% of portfolio
-
Jennison Associates LLC5.87MShares$47.8 Million0.07% of portfolio
-
Invesco Ltd. Atlanta, GA4.1MShares$33.3 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$28.5 Million9.52% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $319M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...